Updated August 2026
Selank Dosage: Research Evidence, Russian Label, and Study Protocol
Research note: Selank (TKPRPGP, MW ~751.9 Da) is a synthetic tuftsin-related heptapeptide with a Russian 0.15% intranasal medicinal product: 2 drops per nostril three times daily for 14 days (~900 mcg/day if 75 mcg/drop). The best-documented historical trial used 2,700 mcg/day (900 mcg × 3) for 14 days. Human evidence is limited small Russian studies. No validated SC dose, human PK, or weight-based formula. ≠ N-acetyl Selank · ≠ N-Acetyl Selank Amidate.
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) extends tuftsin (Thr-Lys-Pro-Arg) with Pro-Gly-Pro for metabolic stability. It is registered in Russia as 0.15% intranasal drops (Selank diacetate) for anxiety- and stress-related indications.
Current manufacturer instructions: two drops into each nostril three times daily for 14 days, with possible repeat after 1–3 weeks following medical consultation. At 0.15% (1.5 mg/mL) and the historically referenced 75 mcg/drop, four drops per administration ≈ 300 mcg and three daily administrations ≈ 900 mcg/day — but drop count is more authoritative than calculated mcg unless delivered volume is validated.
The clinical-pharmacology dissertation underlying Zozulia 2008 describes 2,700 mcg/day intranasally in three divided doses for 14 days. Label exposure and trial exposure are not identical and should not be merged without dose-ranging study.
Selank dosage in 30 seconds
| Question | Current answer |
|---|---|
| Sequence | TKPRPGP · H-TKPRPGP-OH · ~751.9 Da |
| Russian label | 2 drops/nostril × 3/day × 14 days |
| Approx. label daily | ~900 mcg/day (75 mcg/drop assumption) |
| Historical trial | 2,700 mcg/day · 900 mcg × 3 · 14 days |
| Online IN range | 200–500 mcg/admin · anecdotal |
| Human SC dose | None validated |
| Rodent anchor | 300 mcg/kg · not a human dose |
| U.S. label | None · FDA flags selank acetate (TP-7) compounding |
Compound identity
Selank, Selank diacetate, N-acetyl Selank, and N-Acetyl Selank Amidate are frequently treated as interchangeable online. They are not equivalent on a mass-for-mass or evidence basis. This page covers parent Selank (TKPRPGP).
Identity gate
Parent Selank (TKPRPGP) vs diacetate · N-acetyl · amidated analog
This page's subject — tuftsin-related heptapeptide TKPRPGP
MW ~751.9 Da · CAS 129954-34-3 · PubChem CID 11765600. Russian 0.15% intranasal medicinal product and human GAD studies refer to parent Selank (often as diacetate salt).
Selank and related molecules
Molecular comparison
Parent Selank · diacetate product · terminal-modified analogs
| Compound | Sequence | MW | Distinction |
|---|---|---|---|
| Selank (parent) | H-TKPRPGP-OH | 751.9 Da | This page · Russian IN product |
| Selank diacetate | TKPRPGP · diacetate salt | Salt-dependent | 0.15% nasal drops (Russia) |
| N-acetyl Selank | Ac-TKPRPGP-OH | 793.9 Da | N terminus only modified |
| N-Acetyl Selank Amidate | Ac-TKPRPGP-NH2 | 792.94 Da | Both termini modified · ≠ parent dose |
Regulatory and labeled dosage context
Russia: 0.15% nasal drops — indications include anxiety, neurasthenia, asthenia, mood instability, sleep disturbance, and stress disorders. Contraindicated pregnancy, lactation, under 18.
United States: No prescribing label. FDA lists selank acetate (TP-7) among bulk substances with potential aggregation, immunogenicity, and characterization concerns — relevant to compounded material, not a substitute for the separate Russian product history.
Russian labeled regimen
Drop count → mcg per administration and daily total (0.15% product)
Per administration
300 mcg
2 drops × 2 nostrils
Daily total
900 mcg
14-day course
12.60 mg
Default matches current Russian instructions (2 drops/nostril × 3/day). Drop size varies — labeled drop count is more authoritative than assumed 75 mcg/drop unless validated.
Dosage used in human clinical research
> Selank has human research data, but doses describe study exposure rather than a universal prescribing protocol.
The best traceable documentation: 2,700 mcg/day intranasally, divided into three administrations, for 14 days (dissertation / Zozulia program). Several other reports do not state dose in accessible abstracts — assigning 2,700 mcg without full methods overstates certainty.
Human clinical research
2,700 mcg/day best traceable · several abstracts omit dose
| Study | Dose | Route | Duration | Limit |
|---|---|---|---|---|
| Zozulia 2008GAD/neurasthenia vs medazepam | 2,700 mcg/day3 × 900 mcg | IN drops | 14 days | Small · no placebo · Russian reporting |
| Dissertation (Syunyakov)Pharmaco-EEG · exploratory | 2,700 mcg/day; 900 mcg test3 divided | IN drops | 5–14 days | Underlying dose source for 2008 report |
| Uchakina 2008Th1/Th2 cytokine effects | Not in abstractNot stated | IN Selank | 14 days | Do not assign 2,700 mcg without full methods |
| Medvedev 2014Phobic-anxiety vs phenazepam | Not in abstractCourse | Medicinal product | Course | Dose not reproducible from abstract |
| Medvedev 2015Combination tolerability | Not in abstractAdd-on to phenazepam | Medicinal product | Course | Cannot establish monotherapy efficacy |
Current label versus historical trial exposure
Exposure comparison
Current label (~900 mcg/day) vs historical trial (2,700 mcg/day)
Current Russian labeled regimen
~900 mcg/day if 75 mcg/drop assumed
- Administration
- 2 drops per nostril
- Frequency
- 3 times daily
- Duration
- 14 days
- Repeat
- After 1–3 weeks · medical consultation
- Concentration
- 0.15% (1.5 mg/mL)
- Approx. per dose
- ~300 mcg (4 drops × 75 mcg)
Best-documented historical trial
2,700 mcg/day · 3 × 900 mcg
- Daily total
- 2,700 mcg
- Per administration
- 900 mcg
- Frequency
- 3 times daily
- Duration
- 14 days
- Source
- Clinical-pharmacology dissertation / Zozulia program
- 14-day total
- ~37.8 mg nominal
The paradox: many online protocols use less nominal mass than the historical trial but introduce less-studied routes (SC spray pumps) or longer duration — lower mcg does not automatically mean evidence-based.
Evidence hierarchy for research dosage
Evidence hierarchy
Label + small human program · SC and long-term weak
| Category | Selank evidence | Interpretation |
|---|---|---|
| Current medicinal-product instructions | 2 drops/nostril × 3/day × 14 d | Strongest practical regimen for 0.15% product |
| Human clinical evidence | 2,700 mcg/day × 3 doses × 14 d most traceable | Documented exposure · limited quality |
| Published experimental evidence | Small Russian human studies | Supports research · not broad efficacy proof |
| Preclinical evidence | 300 mcg/kg rodents IN/IP | Mechanistic only · no human conversion |
| Anecdotal research protocol | 200–500 mcg/admin · 1–3× daily | Online convention · inconsistent provenance |
| Insufficient evidence | Injectable cycles · long-term daily use | No validated clinical basis |
Commonly reported research protocols
Reported protocols
Russian label · historical trial · online IN/SC conventions
- Amount
- 2 drops/nostril (~300 mcg/admin)
- Frequency
- 3 times daily
- Route
- Intranasal drops
- Duration
- 14 days
- Evidence basis
- Current Russian label
Cumulative exposure examples
Cumulative exposure
14-day nominal totals — label · trial · online ranges
Daily
900 mcg
14-day total
12.60 mg
Per dose
300 mcg × 3/day
Arithmetic totals only — delivered nasal dose, mucociliary clearance, formulation, and peptide content may differ substantially.
Anecdotal versus clinically studied dosing
Evidence split
Clinical IN record vs anecdotal (often lower mcg, less-studied route)
Clinical and labeled intranasal record
Label ~900 mcg/day · trial 2,700 mcg/day
- Current label
- ~300 mcg × 3/day ≈ 900 mcg/day
- Historical study
- 900 mcg × 3/day = 2,700 mcg/day
- Route
- Intranasal drops
- Duration
- 14 days
- Evidence
- Product instructions + small human program
Anecdotal research reports
Often lower mcg but less-studied route/duration
- Typical amount
- 100–1,500 mcg/day reported
- Route
- IN spray or SC injection
- Duration
- 10 days – 4 weeks; some indefinite
- SC evidence
- Very low · no peer-reviewed human SC dose
- Paradox
- Lower mass ≠ safer if route/duration less studied
Preclinical research dosage
Animal / preclinical — not human dosage. The 300 mcg/kg dose appears repeatedly in rodent work as behaviorally active. It is not a human dose recommendation.
Preclinical anchors
300 mcg/kg rodents repeated — not a human dose
| Model | Dose | Route | Duration | Outcome |
|---|---|---|---|---|
| Wistar rats | 300 mcg/kg | IN | Single · 1–3 h | Frontal-cortex GABAergic gene expression |
| Wistar rats (UCMS) | 300 mcg/kg | IN | 14 days daily | Anxiety-like behavior ± diazepam |
| BALB/c · C57BL/6 mice | 300 mcg/kg/day | IN or IP | 5 days | EPM · GABA/NMDA binding markers |
| Wistar rats (foot-shock) | 100–1,000 mcg/kg | IP | Study-specific | Liver morphology · stress effects |
Research protocol variations
14 days has strongest support from label and human studies. 21–30+ days and 5-on/2-off schedules are predominantly commercial/anecdotal. Intranasal has direct human precedent; subcutaneous requires separate development. Selank + benzodiazepine or Selank + Semax blends lack established combined human doses.
Mechanism relevant to dosage
No single receptor-occupancy target guides dosing. Preclinical threads: GABA-associated binding and gene expression, monoaminergic signaling, enkephalin-degrading enzymes, neurotrophin-associated changes, immune/cytokine modulation. Volkova 2016 (300 mcg/kg) suggests indirect GABAergic modulation rather than simple benzodiazepine-like binding.
Dose escalation
Human studies used fixed regimens — no validated titration by weight or subjective response. Online escalation from 100–250 mcg toward 250–500 mcg is community convention, not dose-response evidence.
Safety, side effects, and monitoring
Safety monitoring
Russian label effects · nasal/CNS domains · FDA compounding note
- Russian label (product)
- Unpleasant taste if drops reach throat; allergic reactions including delayed — frequency not established. No registered overdose cases (limited exposure database).
- Nasal
- Burning, dryness, congestion, epistaxis, mucosal injury, altered smell — monitor with examination and olfaction testing
- Neurologic / psychiatric
- Headache, dizziness, brain fog, activation, sedation, mood change, paradoxical anxiety — structured scales in trials
- FDA compounding (U.S.)
- Selank acetate (TP-7) on withdrawn bulk list — aggregation, impurities, immunogenicity, characterization concerns
Product-quality requirements
HPLC purity ≠ identity. Require intact-mass LC-MS for TKPRPGP, sequence confirmation, peptide-content assay, related-peptide profiling, and for nasal formulations: delivered-dose uniformity, pH, osmolality, and stability. Drop volume and spray actuation are not interchangeable without measurement.
Complete proposed dose-ranging research protocol
Phase 2a: randomized, double-blind, placebo-controlled comparison of 900 mcg/day (label-like) vs 2,700 mcg/day (historical trial) vs placebo × 14 days in generalized anxiety disorder. PK lead-in (18 participants): 300 mcg single → 900 mcg single → 900 mcg × 3/day. Target 150 participants (50/arm).
Proposed Phase 2a design
PK lead-in → 900 vs 2,700 mcg/day × 14 days vs placebo
PK lead-in (18 participants)
| Cohort | Dose | Plan |
|---|---|---|
| P1 | 300 mcg single IN | Sentinel: first 2 dosed 24 h apart |
| P2 | 900 mcg single IN | After P1 safety review |
| P3 | 900 mcg × 3 in one day | ~6 h between doses · trough sampling |
Main trial — 150 participants · HAM-A primary · 14 days
| Arm | Schedule | Daily total |
|---|---|---|
| Vehicle × 3 | 0/0/0 mcg | Placebo |
| 900 mcg/day × 14 d | 300/300/300 mcg | 900 mcg/day |
| 2,700 mcg/day × 14 d | 900/900/900 mcg | 2700 mcg/day |
Low arm approximates current Russian labeled exposure; high arm replicates best-documented historical trial. Requires GMP metered pump, validated TKPRPGP assay, and regulatory approval.
Investigator-ready framework requiring regulatory authorization, GMP metered nasal formulation, validated TKPRPGP assay, and independent ethics review — not a personal-use schedule.
Claims versus evidence
Claim checker
Common Selank claims vs the evidence record
250–500 mcg is the standard Selank dose
Overstated
Common online range, not the best-documented clinical standard. Label ≈300 mcg/admin; historical trial used 900 mcg/admin.
Dosage evidence ladder
Dosage evidence ladder
Russian label strongest · SC and long-term weakest
| Dosage information | Evidence | Status |
|---|---|---|
| U.S. labeled dosing | None | None |
| Russian labeled dosing | 0.15% IN · 2 drops/nostril × 3/day × 14 d | Established for product |
| Human clinical-trial dosing | 2,700 mcg/day × 14 d clearest | Limited · small studies |
| Preclinical dosing | 300 mcg/kg rodents repeated | Mechanistic only |
| Anecdotal IN protocols | 200–500 mcg/admin common | Low · inconsistently sourced |
| Anecdotal SC protocols | 100–500 mcg/day reported | Very low |
| Long-term / weight-based human | Not established | None |
Bottom line
The strongest current regimen is the Russian 0.15% product instruction: two drops per nostril three times daily for 14 days. The strongest historical trial dose is 2,700 mcg/day in three divided intranasal doses for 14 days — not the same as the label.
Intranasal delivery has direct human precedent; subcutaneous dosing does not. Animal 300 mcg/kg stays preclinical. The highest-value next study: placebo-controlled 900 vs 2,700 mcg/day with validated PK and nasal delivery.
Label ≈900 mcg/day · Trial 2,700 mcg/day · Do not merge. Drops ≠ sprays without measurement.
Frequently asked questions
What is the current Selank nasal-drop dosage?
Russian instructions: two drops in each nostril three times daily for 14 days. Repeat course possible after 1–3 weeks following medical consultation.
How many micrograms is the Russian label dose?
At 0.15% (1.5 mg/mL) and ~75 mcg/drop historically referenced, four drops per administration ≈ 300 mcg and three daily doses ≈ 900 mcg/day. Drop size varies — validate delivered mass before claiming exact micrograms.
What dose was used in the best-known human study?
The 2008 clinical program used 2,700 mcg/day intranasally, divided into three 900-mcg administrations, for 14 days.
Is 250–500 mcg the standard Selank dose?
It is a common online range but not the best-documented clinical standard. It may overlap per-administration interpretations of the label, but provenance is often unclear (per spray, nostril, or day).
Is Selank dosed by body weight?
Not in established human protocols. Weight-based figures such as 300 mcg/kg come from animal research.
Is there a validated injectable Selank dose?
No peer-reviewed human subcutaneous dose-finding study was located. Injectable schedules are community conventions.
Is N-Acetyl Selank Amidate the same dose as Selank?
No. The amidated analog (Ac-TKPRPGP-NH2) is a separate test article with no validated dose equivalence to parent Selank.
What is the maximum Selank dose?
Maximum tolerated human dose not established. Largest clearly documented daily amount in the principal program is 2,700 mcg/day — not a universal maximum or recommendation.
Does Selank require titration?
Russian label and best-documented human study used fixed dosing. Online titration schedules are anecdotal.
How long can Selank be used?
Most human courses lasted about 14 days. Evidence is inadequate for continuous use over months or years.
References
Selank manufacturer
Current Russian 0.15% nasal-drop instructionsOfficial product labeling.
RLS
Selank 0.15% Russian monographDrug reference dosing.
Zozulia AA et al.
Selank in GAD and neurasthenia2008 · 2,700 mcg/day program.
Syunyakov TS
Clinical-pharmacology dissertation2,700 mcg/day · 3 divided IN doses.
Uchakina ON et al.
Immunomodulatory effects of Selank2008 · dose not in abstract.
Volkova AA et al.
Selank and GABAergic gene expression2016 · 300 mcg/kg rats.
PubChem
SelankCID 11765600 · 751.9 g/mol.
FDA
Bulk drug substance compounding safetySelank acetate (TP-7) concerns.